August 04, 2017

Zacks Rank: 3-Hold

This is our short term rating system

that serves as a timeliness indicator
for stocks over the next 1 to 3
months. How good is it? See
rankings and related performance
below.

Zacks Annualized
Definition
Rank Return
Strong
1 26.65%
Buy
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
Strong
5 2.56%
Sell
S&P 500 10.28%

Zacks Rank Education - Learn

about the Zacks Rank

Zacks Rank Home - Zacks Rank

resources in one place

Zacks Premium - The way to

access to the Zacks Rank

Style :
The Style
Scores are
a
complementary
set of
indicators
to use
alongside
the Zacks
Rank. It
allows the
user to
better
focus on
the stocks
that are
the best fit
for his or
her
personal
trading
style.

The scores
are based
on the
trading
styles of
Value,
Growth,
and
Momentum.
There's
also a
VGM
Score ('V'
for Value,
'G' for
Growth
and 'M'
for
Momentum),
which
combines
 the
weighted
Akorn, Inc. (NASD:AKRX) average of
the
$ 33.45 individual
USD (As of 08/03/2017) style
scores into
one score.

Value
A
Score
Growth
A
Score
Momentum
A
Score
VGM
A
Score

Within
each
Score,
stocks are
graded
into five
groups: A,
B, C, D
and F. As
you might
remember
from your
school
days, an
A, is
better than
a B; a B is
better than
a C; a C is
better than
a D; and a
D is better
than an F.

As an
investor,
you want
to buy
stocks
with the
highest
probability
of
success.
That
means you
want to
buy stocks
with a
Zacks
Rank #1
or #2,
Strong
Buy or
Buy,
which also
has a
Score of
an A or a
B in your
personal
trading
style.

Zacks
Style
Scores
Education
- Learn
more
about the
Zacks
Style
 Scores

| | |
Value:
Growth: Momentum: VGM:
52 Week High-Low $35.40 - $17.61
20 Day Average Volume2,642,524
Beta 1.36
Market Cap 4.18 B
Dividend / Div Yld $0.00 / 0.00%
Industry Medical - Generi..
Industry Rank 203 / 265 (Bot 23%)
Proj. EPS Growth (Q1) -33.93%
Proj. EPS Growth (F1) -30.18%
P/E (F1) 22.08
Last EPS Surprise 1.82%
Avg. Last 4 Surprises 3.13%
Next Report Date NA
Earnings ESP 0.00%

Price, Consensus & Surprise

Agreement Estimate Revisions (60 Days)

Q1 Q2 F1 F2
# of Analysts 4 4 6 2
# of Revisions 0 0 0 0
# Up 0 0 0 0
# Down 0 0 0 0
% Revision Agreement:

Magnitude Consensus Estimate Trend (60 Days)

Q1 Q2 F1 F2
Current 0.37 0.38 1.52 1.81
7 Days Ago 0.37 0.38 1.52 1.81
30 Days Ago0.37 0.38 1.52 1.81
60 Days Ago0.37 0.38 1.52 1.81
Trend of
Estimate
Revisions:
0% 0% 0% 0%

Industry Comparison Medical - Generi.. | Position in Industry: 1 of 22

Industry Peers
AKRX
Hist. EPS Growth (3-5 yrs) NA
Proj. Sales Growth (F1/F0) -7.20%
Net Margin 12.15%
Return on Equity 21.31%
Debt/Capital 47.86%
P/E (F1) 22.10
Price/Sales (P/S) 4.10
Price/Book (P/B) 4.72
Price/Cash Flow (P/CF) 11.25
YTD % Price Change 53.37%
X Industry
-0.77%
0.00%
-17.73%
-29.88%
21.29%
22.10
3.51
2.87
16.60
1.60%
S&P 500
7.16%
5.19%
9.86%
15.93%
41.65%
18.98
2.50
3.22
13.49
9.89%
MNK IPXL AMPH
35.86% -4.92% -19.00%
-10.51% -4.82% 1.91%
16.01% -71.50% 3.54%
16.33% 7.71% 2.69%
52.71% 58.58% 8.73%
5.79 27.44 63.40
1.24 1.67 2.91
0.89 2.43 2.26
165.18 7.19 28.83
-12.55% 34.34% -12.81%

Description Medical > Drugs > Medical - Generic Drugs

Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia
and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists,
wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services.

Learn More about Zacks Rank and Style Scores